Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213804) titled 'A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer' on Oct. 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Eli Lilly and Company
Condition:
Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Neoplasm Metastasis
Intervention:
Drug: LY4170156
Drug: Paclitaxel
Drug: Topotecan
Drug: Gemcitabine
Drug: Pegylated liposomal doxorubicin
Drug: MIRV
Drug: Bevacizumab
Recruitment Status: Not rec...